355 related articles for article (PubMed ID: 31578080)
1. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.
Madsen CM; Kamstrup PR; Langsted A; Varbo A; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):255-266. PubMed ID: 31578080
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.
Small AM; Pournamdari A; Melloni GEM; Scirica BM; Bhatt DL; Raz I; Braunwald E; Giugliano RP; Sabatine MS; Peloso GM; Marston NA; Natarajan P
JAMA Cardiol; 2024 Apr; 9(4):385-391. PubMed ID: 38353970
[TBL] [Abstract][Full Text] [Related]
3. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
Klingel R; Heibges A; Fassbender C;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.
Verbeek R; Hoogeveen RM; Langsted A; Stiekema LCA; Verweij SL; Hovingh GK; Wareham NJ; Khaw KT; Boekholdt SM; Nordestgaard BG; Stroes ESG
Eur Heart J; 2018 Jul; 39(27):2589-2596. PubMed ID: 29931232
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Leebmann J; Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Maerz W; Lehmacher W; Heibges A; Klingel R;
Circulation; 2013 Dec; 128(24):2567-76. PubMed ID: 24056686
[TBL] [Abstract][Full Text] [Related]
6. Practical management of dyslipidemia with elevated lipoprotein(a).
Riche DM; East HE; Priest HM
J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
[TBL] [Abstract][Full Text] [Related]
7. Contribution of remnant cholesterol to cardiovascular risk.
Langsted A; Madsen CM; Nordestgaard BG
J Intern Med; 2020 Jul; 288(1):116-127. PubMed ID: 32181933
[TBL] [Abstract][Full Text] [Related]
8. Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy.
Waissi F; Dekker M; Timmerman N; Hoogeveen RM; van Bennekom J; Dzobo KE; Schnitzler JG; Pasterkamp G; Grobbee DE; de Borst GJ; Stroes ESG; de Kleijn DPV; Kroon J
Stroke; 2020 Oct; 51(10):2972-2982. PubMed ID: 32878565
[TBL] [Abstract][Full Text] [Related]
9. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.
Kamstrup PR; Tybjaerg-Hansen A; Steffensen R; Nordestgaard BG
JAMA; 2009 Jun; 301(22):2331-9. PubMed ID: 19509380
[TBL] [Abstract][Full Text] [Related]
10. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
Burgess S; Ference BA; Staley JR; Freitag DF; Mason AM; Nielsen SF; Willeit P; Young R; Surendran P; Karthikeyan S; Bolton TR; Peters JE; Kamstrup PR; Tybjærg-Hansen A; Benn M; Langsted A; Schnohr P; Vedel-Krogh S; Kobylecki CJ; Ford I; Packard C; Trompet S; Jukema JW; Sattar N; Di Angelantonio E; Saleheen D; Howson JMM; Nordestgaard BG; Butterworth AS; Danesh J;
JAMA Cardiol; 2018 Jul; 3(7):619-627. PubMed ID: 29926099
[TBL] [Abstract][Full Text] [Related]
11. Lp(a): Addressing a Target for Cardiovascular Disease Prevention.
Vasquez N; Joshi PH
Curr Cardiol Rep; 2019 Jul; 21(9):102. PubMed ID: 31367887
[TBL] [Abstract][Full Text] [Related]
12. Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study.
Perrot N; Verbeek R; Sandhu M; Boekholdt SM; Hovingh GK; Wareham NJ; Khaw KT; Arsenault BJ
Atherosclerosis; 2017 Jan; 256():47-52. PubMed ID: 27998826
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events.
Thomas PE; Vedel-Krogh S; Nielsen SF; Nordestgaard BG; Kamstrup PR
J Am Coll Cardiol; 2023 Dec; 82(24):2265-2276. PubMed ID: 38057068
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions.
Welsh P; Welsh C; Celis-Morales CA; Brown R; Ho FK; Ferguson LD; Mark PB; Lewsey J; Gray SR; Lyall DM; Gill JMR; Pell JP; de Lemos JA; Willeit P; Sattar N
Eur J Prev Cardiol; 2022 Feb; 28(18):1991-2000. PubMed ID: 33624048
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
[TBL] [Abstract][Full Text] [Related]
16. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
Grützmacher P; Öhm B; Szymczak S; Dorbath C; Brzoska M; Kleinert C
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):22-26. PubMed ID: 28233269
[TBL] [Abstract][Full Text] [Related]
17. Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.
Fras Z
Anatol J Cardiol; 2020 Jan; 23(2):60-69. PubMed ID: 32011323
[TBL] [Abstract][Full Text] [Related]
18. Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes.
Berk KA; Yahya R; Verhoeven AJM; Touw J; Leijten FP; van Rossum EF; Wester VL; Lips MA; Pijl H; Timman R; Erhart G; Kronenberg F; Roeters van Lennep JE; Sijbrands EJG; Mulder MT
Diabetologia; 2017 Jun; 60(6):989-997. PubMed ID: 28386638
[TBL] [Abstract][Full Text] [Related]
19. High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis.
Zhang W; Speiser JL; Ye F; Tsai MY; Cainzos-Achirica M; Nasir K; Herrington DM; Shapiro MD
J Am Coll Cardiol; 2021 Sep; 78(11):1083-1094. PubMed ID: 34503676
[TBL] [Abstract][Full Text] [Related]
20. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
